Pfizer Experiences Revenue Growth for the First Time Since 2022 COVID Peak
Tuesday, 30 July 2024, 12:56
Pfizer's Financial Performance Overview
On Tuesday, Pfizer Inc. (NYSE:PFE) announced its second-quarter financial results, highlighting a notable period for the company.
Key Financial Results
- Adjusted EPS: $0.60, down 11% year over year, surpassing the consensus estimate of $0.46.
- Sales: $13.28 billion, up 2% from last year, exceeding the forecast of $13.02 billion.
Factors Contributing to Growth
The revenue increase is largely attributed to:
- Growth from acquired products.
- Strong performance of key in-line products.
- Recent successful commercial launches.
This positive performance helped to offset the anticipated decline in Comirnaty.
Conclusion
Pfizer’s revenue growth is a significant indicator of the company’s recovery and future potential, as evidenced by its revised annual guidance.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.